18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Proportion of aDBS Subjects With "On" Time Without Troublesome Dyskinesia Exceeding the Threshold.Primary· About one month
In the PD Home Diary, in 30-minute intervals, patients recorded whether they were in the "On" condition (with dyskinesia, with non-troublesome dyskinesia, with troublesome dyskinesia), "Off" condition, or asleep. The "On" time without troublesome dyskinesia combined the categories of "On" time without dyskinesia and "On" time with non-troublesome dyskinesia. The PD Home Diary was collected at both the cDBS Baseline and aDBS Evaluation Phases. The threshold was determined using the hours of "On" time without troublesome dyskinesia for aDBS is no worse than 2 hours per day less than cDBS. The pr
Group
Value
95% CI
Primary Cohort aDBS Single Threshold
78.9
59.4 – NA
Primary Cohort aDBS Dual Threshold
91
75.6 – NA
Stimulation Energy UseSecondary· About one month
Total electrical energy delivered (TEED) for aDBS as compared with cDBS, calculated as TEED at aDBS - TEED at cDBS.
Group
Value
95% CI
aDBS Single Threshold
-22.3
-42.0 – -2.6
aDBS Dual Threshold
-22.3
-48 – 3.3
Safety (Stimulation-related AEs)Secondary· About one month
To characterize stimulation-related adverse events
Group
Value
95% CI
Primary Cohort at cDBS Baseline
3
Primary Cohort: aDBS Single Threshold Mode
8
Primary Cohort: aDBS Dual Threshold Mode
5
Adverse events — posted to ClinicalTrials.gov
Time frame: From subject enrollment to subject last visit or subject exit, an average of 15 months..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Enrollment to Randomization
Serious: 0/85 (0%)
Deaths: 0/85
Primary Cohort aDBS Single Threshold Mode
Serious: 1/35 (3%)
Deaths: 1/35
Primary Cohort aDBS Dual Threshold Mode
Serious: 0/40 (0%)
Deaths: 0/40
Directional Stimulation Cohort aDBS Single Threshold Mode
NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease
· NA
· recruiting
NCT06791902 — Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in P
· NA
· recruiting
NCT05402163 — CANadian Adaptive DBS TriAl
· NA
· recruiting
NCT07106242 — Adaptive Deep Brain Stimulation (aDBS) Study (Early Adapter) Part II
· NA
· completed
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other MedtronicNeuro trials
Trials by the same sponsor.
NCT05775510 — Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chro
· terminated
NCT05226286 — Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)
· NA
· completed
NCT05200923 — Pelvic Health Electrically Evoked Recording (PEER) 2 Study
· NA
· recruiting
NCT05177354 — Medtronic Closed-Loop Spinal Cord Stimulation System
· NA
· completed
NCT07106242 — Adaptive Deep Brain Stimulation (aDBS) Study (Early Adapter) Part II
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedtronicNeuro
Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04547712.